FDA expands Zytiga's use for late-stage prostate cancer

December 10, 2012

FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.